Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
Go back to Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 67.29 +1.59 (2.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.70 | 52 Week High | $19.98 | |||
| Open | $64.10 | 52 Week Low | $10.52 | |||
| Day High | $67.79 | P/E | N/A | |||
| Day Low | $64.10 | EPS | $-1.45 | |||
| Volume | 610,082 | |||||
